摘要
目的研究复方苦参注射液通过JAK2/STAT3信号通路对肝癌HepG2细胞增殖、侵袭的调控作用.方法培养肝癌HepG2细胞并分组,对照组用不含药物的培养基处理、复方苦参组用含有2%复方苦参注射液的培养基处理、复方苦参+空白质粒组用含有2%复方苦参注射液的培养基处理并转染空白质粒、复方苦参+JAK2质粒组用含有2%复方苦参注射液的培养基处理并转染表达JAK2的质粒.检测细胞增殖活力、侵袭活力及增殖基因、侵袭基因、JAK2、STAT3的表达量.结果复方苦参组、复方苦参+空白质粒组的增殖活力、侵袭活力及CyclinD1、c-myc、Bcl-xL、MMP2、MMP9、p-JAK2、p-STAT3的表达量均明显低于对照组(P<0.05);复方苦参+JAK2质粒组的增殖活力、侵袭活力及CyclinD1、c-myc、Bcl-xL、MMP2、MMP9、p-JAK2、p-STAT3的表达量均明显高于复方苦参+空白质粒组(P<0.05).结论复方苦参注射液对肝癌HepG2细胞增殖、侵袭具有抑制作用且该作用与抑制JAK2/STAT3信号通路有关.
Objective To study the effect of Compound Sophora Flavescens Injection on proliferation and invasion of HepG2 cells via JAK2/STAT3 signaling pathway.Methods HepG2 cells were cultured and grouped.The control group was treated with drug-free medium,the compound Sophora flavescens group was treated with medium containing 2%compound Sophora flavescens injection,the compound Sophora flavescens+blank plasmid group was treated with medium containing 2%compound Sophora flavescens injection and transfected with blank plasmid,and the compound Sophora flavescens+JAK2 plasmid group was treated with 2%compound Sophora flavescens and transfected with plasmid expressing JAK2.Cell proliferation viability,invasive viability,expression of proliferation genes,invasive genes,JAK2 and STAT3 were detected.Results The proliferation viability,invasive viability and the expression of CyclinD1,c-myc,Bcl-xL,MMP2,MMP9,p-JAK2 and p-STAT3 in the compound Sophora flavescens group and the compound Sophora flavescens+blank plasmid group were significantly lower than those in the control group(P<0.05);the proliferation viability,invasive viability and the expression of CyclinD1,c-myc,Bcl-xL,MMP2,MMP9,p-JAK2 and p-STAT3 in the compound Sophora flavescens+JAK2 plasmid group were significantly higher than those of the compound Sophora flavescens+blank plasmid group(P<0.05).Conclusion Compound Sophora flavescens injection can inhibit the proliferation and invasion of HepG2 cells,which is related to the inhibition of JAK2/STAT3 signaling pathway.
作者
张大为
张海光
王丽莉
郝春海
马龙滨
何津
张景华
ZHANG Da-wei;ZHANG Hai-guang;WANG Li-li(The People’s Hospital of Tangshan,Tangshan 063000,China)
出处
《肝胆外科杂志》
2020年第2期145-148,共4页
Journal of Hepatobiliary Surgery
基金
河北省中医药管理局科研计划项目(编号:2018335)
作者简介
通讯作者:何津
